Predicting the risk of developing new cerebral lesions after stereotactic radiosurgery or fractionated stereotactic radiotherapy for brain metastases from renal cell carcinoma

Dirk Rades, Liesa Dziggel, Oliver Blanck, Niklas Gebauer, Tobias Bartscht, Steven E. Schild

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Aim: To create an instrument for estimating the risk of new brain metastases after stereotactic radiosurgery (SRS) or fractionated stereotactic radiotherapy (FSRT) alone in patients with renal cell carcinoma (RCC). Patients and Methods: In 45 patients with 1-3 brain metastases, seven characteristics were analyzed for association with freedom from new brain metastases (age, gender, performance score, number and sites of brain metastases, extra-cerebral metastasis, interval from RCC diagnosis to SRS/FSRT). Results: Lower risk of subsequent brain lesions after RT was associated with single metastasis (p=0.043) and supratentorial involvement only (p=0.018). Scoring points were: One metastasis=1, 2-3 metastases=0, supratentorial alone=1, infratentorial with/without supratentorial=0. Scores of 0, 1 and 2 points were associated with 6-month rates of freedom from subsequent brain lesions of 25%, 74% and 92% (p=0.008). After combining groups with 1 and 2 points, 6-month rates were 25% for those with 0 points and 83% for those with 1-2 points (p=0.002). Conclusion: Two groups were identified with different risks of new brain metastases after SRS or FSRT alone. High-risk patients may benefit from additional whole-brain irradiation.

Original languageEnglish (US)
Pages (from-to)2973-2976
Number of pages4
JournalAnticancer Research
Volume38
Issue number5
DOIs
StatePublished - May 1 2018

Fingerprint

Radiosurgery
Renal Cell Carcinoma
Radiotherapy
Neoplasm Metastasis
Brain

Keywords

  • Brain metastases
  • Fractionated stereotactic radiotherapy
  • Freedom from new brain metastases
  • Renal cell carcinoma
  • Scoring instrument
  • Stereotactic radiosurgery

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Predicting the risk of developing new cerebral lesions after stereotactic radiosurgery or fractionated stereotactic radiotherapy for brain metastases from renal cell carcinoma. / Rades, Dirk; Dziggel, Liesa; Blanck, Oliver; Gebauer, Niklas; Bartscht, Tobias; Schild, Steven E.

In: Anticancer Research, Vol. 38, No. 5, 01.05.2018, p. 2973-2976.

Research output: Contribution to journalArticle

Rades, Dirk ; Dziggel, Liesa ; Blanck, Oliver ; Gebauer, Niklas ; Bartscht, Tobias ; Schild, Steven E. / Predicting the risk of developing new cerebral lesions after stereotactic radiosurgery or fractionated stereotactic radiotherapy for brain metastases from renal cell carcinoma. In: Anticancer Research. 2018 ; Vol. 38, No. 5. pp. 2973-2976.
@article{2d502b7af1a2424686e8b93808c7b3d2,
title = "Predicting the risk of developing new cerebral lesions after stereotactic radiosurgery or fractionated stereotactic radiotherapy for brain metastases from renal cell carcinoma",
abstract = "Aim: To create an instrument for estimating the risk of new brain metastases after stereotactic radiosurgery (SRS) or fractionated stereotactic radiotherapy (FSRT) alone in patients with renal cell carcinoma (RCC). Patients and Methods: In 45 patients with 1-3 brain metastases, seven characteristics were analyzed for association with freedom from new brain metastases (age, gender, performance score, number and sites of brain metastases, extra-cerebral metastasis, interval from RCC diagnosis to SRS/FSRT). Results: Lower risk of subsequent brain lesions after RT was associated with single metastasis (p=0.043) and supratentorial involvement only (p=0.018). Scoring points were: One metastasis=1, 2-3 metastases=0, supratentorial alone=1, infratentorial with/without supratentorial=0. Scores of 0, 1 and 2 points were associated with 6-month rates of freedom from subsequent brain lesions of 25{\%}, 74{\%} and 92{\%} (p=0.008). After combining groups with 1 and 2 points, 6-month rates were 25{\%} for those with 0 points and 83{\%} for those with 1-2 points (p=0.002). Conclusion: Two groups were identified with different risks of new brain metastases after SRS or FSRT alone. High-risk patients may benefit from additional whole-brain irradiation.",
keywords = "Brain metastases, Fractionated stereotactic radiotherapy, Freedom from new brain metastases, Renal cell carcinoma, Scoring instrument, Stereotactic radiosurgery",
author = "Dirk Rades and Liesa Dziggel and Oliver Blanck and Niklas Gebauer and Tobias Bartscht and Schild, {Steven E.}",
year = "2018",
month = "5",
day = "1",
doi = "10.21873/anticanres.12548",
language = "English (US)",
volume = "38",
pages = "2973--2976",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "5",

}

TY - JOUR

T1 - Predicting the risk of developing new cerebral lesions after stereotactic radiosurgery or fractionated stereotactic radiotherapy for brain metastases from renal cell carcinoma

AU - Rades, Dirk

AU - Dziggel, Liesa

AU - Blanck, Oliver

AU - Gebauer, Niklas

AU - Bartscht, Tobias

AU - Schild, Steven E.

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Aim: To create an instrument for estimating the risk of new brain metastases after stereotactic radiosurgery (SRS) or fractionated stereotactic radiotherapy (FSRT) alone in patients with renal cell carcinoma (RCC). Patients and Methods: In 45 patients with 1-3 brain metastases, seven characteristics were analyzed for association with freedom from new brain metastases (age, gender, performance score, number and sites of brain metastases, extra-cerebral metastasis, interval from RCC diagnosis to SRS/FSRT). Results: Lower risk of subsequent brain lesions after RT was associated with single metastasis (p=0.043) and supratentorial involvement only (p=0.018). Scoring points were: One metastasis=1, 2-3 metastases=0, supratentorial alone=1, infratentorial with/without supratentorial=0. Scores of 0, 1 and 2 points were associated with 6-month rates of freedom from subsequent brain lesions of 25%, 74% and 92% (p=0.008). After combining groups with 1 and 2 points, 6-month rates were 25% for those with 0 points and 83% for those with 1-2 points (p=0.002). Conclusion: Two groups were identified with different risks of new brain metastases after SRS or FSRT alone. High-risk patients may benefit from additional whole-brain irradiation.

AB - Aim: To create an instrument for estimating the risk of new brain metastases after stereotactic radiosurgery (SRS) or fractionated stereotactic radiotherapy (FSRT) alone in patients with renal cell carcinoma (RCC). Patients and Methods: In 45 patients with 1-3 brain metastases, seven characteristics were analyzed for association with freedom from new brain metastases (age, gender, performance score, number and sites of brain metastases, extra-cerebral metastasis, interval from RCC diagnosis to SRS/FSRT). Results: Lower risk of subsequent brain lesions after RT was associated with single metastasis (p=0.043) and supratentorial involvement only (p=0.018). Scoring points were: One metastasis=1, 2-3 metastases=0, supratentorial alone=1, infratentorial with/without supratentorial=0. Scores of 0, 1 and 2 points were associated with 6-month rates of freedom from subsequent brain lesions of 25%, 74% and 92% (p=0.008). After combining groups with 1 and 2 points, 6-month rates were 25% for those with 0 points and 83% for those with 1-2 points (p=0.002). Conclusion: Two groups were identified with different risks of new brain metastases after SRS or FSRT alone. High-risk patients may benefit from additional whole-brain irradiation.

KW - Brain metastases

KW - Fractionated stereotactic radiotherapy

KW - Freedom from new brain metastases

KW - Renal cell carcinoma

KW - Scoring instrument

KW - Stereotactic radiosurgery

UR - http://www.scopus.com/inward/record.url?scp=85046501671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046501671&partnerID=8YFLogxK

U2 - 10.21873/anticanres.12548

DO - 10.21873/anticanres.12548

M3 - Article

C2 - 29715126

AN - SCOPUS:85046501671

VL - 38

SP - 2973

EP - 2976

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 5

ER -